The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials by Tabrizi, R. et al.
Contents lists available at ScienceDirect
Pharmacological Research
journal homepage: www.elsevier.com/locate/yphrs
The effects of statin use on inflammatory markers among patients with
metabolic syndrome and related disorders: A systematic review and meta-
analysis of randomized controlled trials
Reza Tabrizia, Omid Reza Tamtajib, Naghmeh Mirhosseinic, Kamran B. Lankaranid,
Maryam Akbaria, Ehsan Dadgostare, Afshin Borhani-Haghighif, Payam Peymanid,
Fariba Ahmadizarg, Zatollah Asemih,⁎
aHealth Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
b Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran
c School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada
dHealth Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
eHalal Research Center of IRI, FDA, Tehran, Iran
f Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
g Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
h Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
A R T I C L E I N F O
Keywords:
Statin use
Inflammatory markers
Meta-analysis
Metabolic syndrome
Randomized control trial
A B S T R A C T
Current evidence suggests that statin use decreases the incidence of cardiovascular diseases (CVD) through
reducing LDL cholesterol and decreasing inflammation. Metabolic syndrome (MetS) is usually associated with
increased inflammatory markers and increased risk of CVD. We conducted a systematic review and meta-analysis
to determine the effect of statin use on inflammatory markers including C-reactive protein (CRP), tumor necrosis
factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1) among patients with MetS and related disorders.
PubMed, EMBASE, Web of Science databases, and Cochrane Library were searched for randomized controlled
trials (RCTs) through April 2018. Three independent investigators evaluated study eligibilities, extracted data,
and assessed study quality using the Cochrane Collaboration risk of bias tool and Jadad's quality scales.
Heterogeneity was determined using Cochran’s Q statistic and I-square (I2) test. Based on the heterogeneity
results, we pooled data using random-effect or fixed effect models presented as standardized mean differences
(SMD) and corresponding 95% confidence intervals (CI). One hundred thirteen RCTs (19,644 patients) were
included in our meta-analysis. The pooled results using random effects model showed that statin use statistically
significantly decreased CRP level (SMD= -0.97; 95% CI, -1.10, -0.85; P < 0.001; I2: 95.1%), TNF-α (SMD=
-1.88; 95% CI, -2.40, -1.38; P < 0.001; I2: 97.2%), IL-6 (SMD= -1.67; 95% CI, -1.98, -1.34; P < 0.001; I2:
96.5%), and IL-1 concentrations (SMD= -8.35; 95% CI, -10.49, -6.22; P < 0.001; I2: 98.4%) among patients
with MetS and related disorders. Our meta-analysis showed beneficial effects of statin use on reducing in-
flammatory markers in patients with MetS and related disorders.
1. Introduction
Increased inflammatory cytokines have had a major contribution to
atherosclerosis and cardiovascular disease (CVD) events [1]. Statins are
known to affect certain inflammatory factors [2], though the dose-re-
sponse effect is mostly unknown. Moreover, chronic inflammation in-
creases the risk of metabolic disorders including type 2 diabetes mellitus
(T2DM) [3]. Reduced adiponectin levels occur in patients with T2DM
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and metabolic syndrome (MetS) [4] has been associated with increased
levels of inflammatory markers, such as C-reactive protein (CRP) [5].
Study participants were considered to have MetS according to the criteria
of the National Cholesterol Education Program (NCEP) Adult Treatment
Panel III when 3 or more of the following criteria were present: fasting
hyperglycemia ≥100mg/dl or under drug treatment for diabetes mel-
litus; systolic arterial blood pressure (SBP) ≥130 mmHg and/or diastolic
arterial blood pressure (DBP) ≥85 mmHg or under drug treatment for
arterial hypertension; serum triglycerides ≥150mg/dl or receiving drug
treatment for dyslipidemia; serum HDL-cholesterol<40mg/dl in men
and<50mg/dl in women or under drug treatment for dyslipidemia;
waist circumference>102 cm in men and>88 cm in women [6]. De-
creased adiponectin levels has also been shown to be correlated with
impaired lipid profile in diabetes and metabolic disorders [7]. Current
evidence suggest that statin use may result in increased adiponectin le-
vels [8], and decreased inflammatory markers.
Several studies have evaluated the effects of statins on inflammatory
markers, yet, the results are inconclusive. In a study by Gruzdeva et al.
[9], atorvastatin use improved adipokines levels and decreased pro-
inflammatory markers in patients diagnosed with myocardial
Fig. 1. Literature search and review flowchart for selection of studies.
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Table 1
Characteristics of included studies.
First Author Publication year Sample size
(control/
intervention)
Country/Population Intervention (name and daily
dose)
Duration Age (control,
intervention)
Presented
data
Jiao et al. [39] 2015 64/62 China/acute coronary syndromes Rosuvastatin 20mg 24 h after
PCI
75.6 ± 7.8,
74.9 ± 8.7
CRP
Wang et al.
[40]
2013 63/62 China/acute coronary syndromes Rosuvastatin 20mg 6 h after
PCI
65.4 ± 10.2,
64.8 ± 11.6
CRP, IL-6
Kinlay et al.
[23]
2003 1186/1216 USA/acute coronary syndromes Atorvastatin 80mg 16 weeks 64 ± 11,
64 ± 12
CRP, IL-6
Patti et al. [41] 2007 85/86 Italy/acute coronary syndromes Atorvastatin 80mg 24 h after
PCI
64 ± 11,
67 ± 10
CRP
Lewandowski
et al. [42]
2008 39/39 Poland/acute coronary syndromes Atorvastatin 20-40mg 5 day 54 ± 8.86,
55 ± 9.42
CRP, TNF-
α, IL-6
Correia et al.
[43]
2003 18/18 Brazil/acute coronary syndromes Atorvastatin 80mg 6 days 65 ± 12,
66 ± 9
CRP
Dohi et al. [44] 2010 84/85 Japan/acute coronary syndromes Atorvastatin 20mg 48 weeks 62.3 ± 10.4,
62.8 ± 10.4
CRP
Yun et al.
(2009)
[45]
2009 220/225 Korea/acute coronary syndromes Rosuvastatin 40mg 24 h after
PCI
64 ± 10,
63 ± 11
CRP
Yun et al.
(2011)
[46]
2011 242/237 Korea/acute coronary syndromes Statins 24 h 63 ± 11,
63 ± 11
CRP
Macin et al.
[47]
2004 46/44 Argentina/acute coronary syndromes Atorvastatin 40mg 1 month 59.3 ± 13.4,
61.1 ± 11.5
CRP
Vasilieva et al.
[48]
2008 20/19 Russia/acute coronary syndromes Atorvastatin
40-80mg+Aspirin
8 days 70.1 ± 2.4,
72.1 ± 1.9
CRP
Wassmann
et al. [49]
2003 14/13 Germany/stable angina Pravastatin 40mg 24 hours
after
treatment
66.4 ± 2.6,
63.7 ± 2.5
CRP
Li et al. (2007)
[50]
2007 16/18 China/unstable angina Simvastatin 10mg after
admission
48 h 57 ± 6,
58 ± 8
CRP
Li et al. (2005)
[51]
2005 17/19 China/unstable angina Atorvastatin 20mg 4 weeks NR CRP
Sawara Y. [52] 2008 16/22 Japan/chronic kidney disease Rosuvastatin 2.5mg 12 weeks 63.8 ± 9.1,
67 ± 7.9
CRP, TNF-
α
Fassett et al.
[53]
2014 17/24 Australia/chronic kidney disease Atorvastatin 10mg 3 years 59.6 ± 15.1,
60.2 ± 15.6
CRP, TNF-
α, IL-6
Verma et al.
[54]
2005 39/44 USA/chronic kidney disease Rosuvastatin 10mg/day 20 weeks 73 ± 10,
74 ± 19
CRP
Jo et al. [55] 2008 99/90 South Korea/chronic kidney disease Simvastatin 80mg 2 days 65 ± 9.3,
66.1 ± 8.2
CRP
Marschang
et al. [56]
2006 16/47 Austria/coronary artery disease Statins 24 weeks 59 ± 2,
61 ± 2
CRP
Chan et al.
[57]
2008 30/30 Taiwan/coronary artery disease Atorvastatin 10mg 24 weeks 66.13 ± 11.50,
63.77 ± 12.73
CRP
Suzuki et al.
[58]
2008 9/10 Japan/coronary artery disease Fluvastatin+Atorvastatin 5
or 10mg
12 weeks 68 ± 7,
71 ± 8
CRP
Azar et al. [59] 2005 26/44 Lebanon/coronary artery disease Statins 48 h after
PCI
59 ± 1,
63 ± 8
CRP, TNF-
α
Karaca et al.
[60]
2003 32/46 Turkey/coronary artery disease Atorvastatin 20mg 4 weeks 52 CRP
Abe et al. [61] 2011 52/52 Japan/diabetic nephropathy 2.5mg/day rosuvastatin,
increased to 10mg/day
24 weeks 64.5 ± 9.6,
64.9 ± 9.2
CRP
Dornbrook-
Lavender
et al. [62]
2005 8/5 USA/dialysis Atorvastatin 10 20 weeks 70 ± 15,
62 ± 15
CRP
Sezer et al.
[63]
2007 20/25 Turkey/dialysis Simvastatin 20mg/day 4 weeks 51.2 ± 13.1,
57.4 ± 11.6
CRP, TNF-
α, IL-6
Arabul et al.
[64]
2008 18/22 Turkey/end-stage renal disease Fluvastatin 40mg 8 weeks 48.7 ± 11.3,
43.6 ± 14.4
CRP
Abulhul et al.
[65]
2012 28/28 Ireland/heart failure Atorvastatin titrated from 10
to 40mg/d over 3 months and
maintained at 40mg/d for a
further 3 months
24 weeks 72 ± 14,
72 ± 9
CRP, TNF-
α, IL-6
Kirmizis et al.
[66]
2010 25/25 Greece/hemodialysis Simvastatin 10mg/day 24 weeks 63 ± 11,
62 ± 13
CRP, IL-6
Chang et al.
[67]
2002 30/28 Korea/hemodialysis Simvastatin, 20mg 8 weeks 63 ± 11,
60 ± 12
CRP
Burmeister
et al. [68]
2009 31/28 Brazil/hemodialysis Rosuvastatin 10mg/day 1 month 60.1 ± 13.8,
53.7 ± 16.6
CRP
Ichihara et al.
[69]
2002 10/12 Japan/hemodialysis with type 2 diabetes Fluvastatin 20 12 weeks 65.8 ± 3,
64.3 ± 3.7
CRP
Ge et al. [70] 2008 65/61 China/hypercholesterolemic Atorvastatin
20mg+ amlodipine 10mg
4 month 64 ± 10,
65 ± 12
CRP
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Table 1 (continued)
First Author Publication year Sample size
(control/
intervention)
Country/Population Intervention (name and daily
dose)
Duration Age (control,
intervention)
Presented
data
Yamagami
et al. [71]
2008 41/40 Japan/hypercholesterolemic Statins 48 weeks 63.4 ± 8.3,
65.4 ± 6.9
CRP, IL-6
Koh et al.
(2004)
[72]
2004 31/32 South Korea/hypercholesterolemic Diet+ simvastatin 20mg 14 weeks 60 CRP, TNF-
α
Koh et al.
(2008)
[73]
2008 30/32 Korea/hypercholesterolemic Simvastatin 10mg/day 8 weeks 57 ± 2,
59 ± 2
CRP
Koh et al.
(2010)
[74]
2010 44/42 Korea/hypercholesterolemic Atorvastatin 10mg 8 weeks 56 ± 10,
54 ± 11
CRP
Koh et al.
(2009)
[75]
2009 42/43 Korea/hypercholesterolemic Simvastatin 20mg/day 8 weeks 58 ± 2,
59 ± 1
CRP
Koh et al.
(2011)
[76]
2011 44/45 Korea/hypercholesterolemic Simvastatin 20mg/day 8 weeks 61 ± 2,
57 ± 2
CRP
Koh et al.
(2015)
[77]
2015 51/51 Korea/hypercholesterolemic Simvastatin 20mg/day 8 weeks 57 ± 8,
59 ± 6
CRP
Nilsson et al.
[78]
2010 39/37 Sweden/hypercholesterolemic Simvastatin 40mg/day 6 weeks 51 ± 5,
50 ± 6
CRP, TNF-
α, IL-6, IL-
1
Ascer et al.
[79]
2004 23/45 Brazil/hypercholesterolemic Atorvastatin 20mg 8 weeks 18-71 CRP, TNF-
α, IL-6, IL-
1
Kuklinska et al.
[80]
2010 60/39 Poland/hypertension Atorvastatin 80mg 12 weeks 53.66 ± 0.14 CRP
McMurray
et al. [81]
2009 779/777 UK/ischemic systolic heart failure with
baseline CRP < 2.0mg/L
Rosuvastatin 10mg 12 weeks 73.2 ± 7.2,
72 ± 7
CRP
Zhang et al.
[82]
2015 41/43 China/metabolic syndrome Simvastatin 40mg 48 weeks 75.19 ± 8.56,
77.17 ± 8.42
CRP, IL-6
Singh et al.
[83]
2008 24/23 USA/metabolic syndrome Atorvastatin 10mg 12 weeks 51 ± 11,
51 ± 12
CRP, TNF-
α
Oguz et al.
[84]
2008 43/42 Turkey/metabolic syndrome Fluvastatin 80mg 6 weeks 55.5 ± 10.46,
56.16 ± 7.56
CRP
Devaraj et al.
[85]
2007 25/25 USA/metabolic syndrome Simvastatin 40mg/day 8 weeks 51 ± 12 CRP, TNF-
α, IL-6, IL-
1
Krysiak et al.
[24]
2010 56/61 Poland/metabolic syndrome with pre-
diabetes
Atorvastatin 40mg 90 days NR CRP, TNF-
α, IL-6, IL-
1
Nafasi et al.
[86]
2014 95/95 Iran/myocardial infarction Atorvastatin 80mg 6 h after
PCI
56.48 ± 10.97,
58.56 ± 8.7
CRP
Chan et al.
[87]
2002 12/13 Australia/obesity Atorvastatin 40mg 6 weeks 53.5 ± 9 CRP, TNF-
α, IL-6
Puurunen et al.
[88]
2013 13/15 Finland/polycystic ovary syndrome Atorvastatin 20mg 12 weeks 40.5 ± 5.9,
38.5 ± 4.8
CRP
Sathyapalan
et al. [89]
2010 18/19 UK/polycystic ovary syndrome Atorvastatin 20mg 12 weeks 26.6 ± 1.2,
28.8 ± 1.8
CRP
Raja-Khan
et al. [90]
2011 11/9 USA/polycystic ovary syndrome Atorvastatin 40mg 6 weeks 33.8 ± 4.3,
29.4 ± 5.8
CRP
Guo et al. [91] 2012 54/47 China/stable atherosclerotic plaques Atorvastatin 10mg 24 weeks 62.64 ± 12.00,
62.07 ± 8.51
CRP
Lunder et al.
[92]
2017 22/22 Slovenia/type 1 diabetes mellitus Fluvastatin 10mg+Valsartan
20mg
30 days 36.3 ± 1.7,
35.6 ± 2.1
CRP
Fegan et al.
[93]
2005 12/20 UK/type 2 diabetes Cerivastatin 0.4 mg 12 weeks 63.3 ± 8.1,
61 ± 9.6
CRP
Konduracka
et al. [94]
2008 50/154 Poland/type 2 diabetes Atorvastatin
40mg+hyperlipidemic diet
24 weeks 36.3 ± 8.3 CRP
van de Ree
et al. [95]
2003 55/67 Netherlands/type 2 diabetes mellitus Atorvastatin 10mg 30 weeks 59.8 ± 7.5,
58.8 ± 7.4
CRP, IL-6
Economides
et al. [96]
2004 18/19 USA/type 2 diabetes mellitus Atorvastatin 20mg 12 weeks 51 ± 14,
55 ± 11
CRP, TNF-
α
Jialal et al.
[25]
2007 26/26 USA/type 1 Diabetes Simvastatin 20mg/day 12 weeks 23.4 ± 9.1,
26.6 ± 13.3
CRP, TNF-
α, IL-6, IL-
1
Ghanim et al.
[97]
2017 10/10 USA/obesity Ezetimibe
10mg+ simvastatin 40mg
6 weeks 51 ± 3,
49 ± 4
CRP, IL-1
Joy et al. [98] 2008 26/19 USA/hemodialysis Atorvastatin 10mg 36 week 63 ± 15,
61 ± 14
CRP
luo et al. [99] 2004 9/11 China/acute myocardial infarction Simvastatin 20mg 3 weeks 65.7 ± 3.6,
67.4 ± 4.5
CRP, IL-6
(continued on next page)
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Table 1 (continued)
First Author Publication year Sample size
(control/
intervention)
Country/Population Intervention (name and daily
dose)
Duration Age (control,
intervention)
Presented
data
Goicoechea
et al. [100]
2006 19/44 Spain/chronic kidney disease Atorvastatin 20mg 6 months 66.2 ± 13.6,
70.0 ± 14.3
CRP, TNF-
α, IL-6, IL-
1
Strazhesko
et al. [101]
2016 38/44 Italy/atherosclerotic Atorvastatin 20mg 12 month 59.2 ± 1.2,
51.4 ± 1.2
CRP, IL-6
Sola et al. [20] 2006 191/255 USA/heart failure Statins 24-month 55.4 ± 6.4,
53.8 ± 5.7
CRP, TNF-
α
Li et al. [102] 2009 13/13 China/end-stage renal disease Simvastatin 20mg 8 week 49.9 ± 14.4,
32.5 ± 7
CRP, IL-6
Doo et al.
[103]
2005 30/20 Korea/unstable angina Statins 24 h after
stenting
62 ± 9,
60 ± 9
CRP, IL-6
Gruzdeva et al.
[104]
2016 66/60 Russia/myocardial infarction Atorvastatin 20mg 12 days 60.4,
56.5
CRP, IL-6
Andreou et al.
[105]
2010 18/21 Greece/heart failure Rosuvastatin 10mg 1 month 65 ± 11,
66 ± 11
CRP, IL-6
Nakagom et al.
[106]
2012 83/63 Japan/heart failure Statins 6 month 64.3 ± 9.9,
66.2 ± 11.9
CRP, TNF-
α, IL-6
Doh et al.
[107]
2012 35/35 Korea/dialysis Rosuvastatin10mg 6 month 48.9 ± 11.7,
48.5 ± 11.3
CRP, IL-6
Gonalves et al.
[108]
2009 39/37 Sweden/hypercholestrolemic Simvastatin 40mg 6 weeks NR CRP, IL-6
Ostadal et al.
[109]
2003 17/13 Czech Republic/myocardial infarction Cerivastatin 0.3 mg 24 h NR CRP, IL-6
Link et al.
[110]
2006 17/18 Germany/acute coronary syndromes Rosuvastatin 20mg 1 day 60 (51.0, 69.5),
55.5 (48.0, 69.0)
CRP, TNF-
α
Yang et al.
[111]
2006 20/40 China/acute coronary syndromes Fluvastatin 40mg 1 week 63.0 ± 10.5,
63.5 ± 9.4
CRP, TNF-
α
Kishimoto
et al. [112]
2010 9/14 Japan/hemodialysis Simvastatin 5mg 1weeks 61.2 ± 8.6,
61.5 ± 5.2
TNF-α, IL-
6
Krysiak et al.
[22]
2011 30/32 Poland/hypercholesterolemia Simvastatin 40mg 30 days 54.3 ± 3.4,
52.3 ± 2.4
TNF-α, IL-
6, IL-1
Stefanadi et al.
[113]
2009 12/12 Greece/myocardial infarction Atorvastatin 10mg 6weeks 58.8 ± 1.8,
59.0 ± 2.5
IL-6
Pereira et al.
[114]
2014 30/162 Brazil/cardiovascular disease Statins 12 months NR IL-6
Tousoulis et al.
[115]
2006 23/24 Greece/unstable angina Atorvastatin 10mg 1weeks 60.1 ± 2.8,
62.1 ± 1.8
TNF-α, IL-
6
Nawawi et al.
[116]
2003 14/41 Malaysia/hypercholesterolemic Atorvastatin 10mg 2 weeks 48.5 ± 1.3,
46 ± 2.9
CRP, IL-6
Gomez-Garcla
et al. [117]
2007 16/16 México/hypertension Rosuvastatin10mg 12 weeks 56 ± 8.8,
54 ± 8.01
TNF-α, IL-
6
Tousoulis et al.
(2005)
[118]
2005 19/19 Greece/heart failure Atorvastatin 10mg 4 weeks 64, 70 TNF-α, IL-
6
Tousoulis et al.
(2005)
[119]
2005 12/14 Greece/heart failure Atorvastatin 10mg 4 week 67.2 ± 5.53,
70.6 ± 6.02
TNF-α, IL-
6
Tousoulis et al.
(2006)
[120]
2005 13/15 Greece/type 2 diabetes Atorvastatin 10mg 4 weeks 58.1, 60.9 TNF-α, IL-
6
Usharani et al.
[121]
2008 21/23 India/type 2 diabetes Atorvastatin 10mg 8 weeks 50.47 ± 10.35,
49.75 ± 8.18
TNF-α, IL-
6
KrysiaK et al.
[122]
2014 18/22 Poland/hypercholesterolemia Simvastatin 40mg 30 days 35–60 TNF-α
Xie et al. [123] 2014 109/109 China/acute coronary syndromes Rosuvastatin 20mg 1 month 59.8 ± 10.5,
61.5 ± 11.4
TNF-α, IL-
6
Koh et al.
[124]
2002 31/32 Korea/coronary artery disease Simvastatin 20mg 14 weeks 62 ± 8,
62 ± 7
TNF-α
Sola et al. [20] 2006 54/54 USA/heart failure Atorvastatin 20mg 12-month 54.1 ± 6.9,
53.3 ± 6.2
CRP, TNF-
α
Zhao et al.
[125]
2004 12/12 China/hypertension Simvastatin 40mg+ valsartan
80mg
1 week 67.3 ± 8.0,
66.1 ± 14
IL-1
Huptas et al.
[126]
2006 10/10 Germany/metabolic syndrome Atorvastatin 10mg/day 6 weeks 40 ± 12 CRP, IL-6
Hu et al. [21] 2009 20/23 China/type 2 diabetic patients with
atherosclerosis
Simvastatin 40mg/daily 12 weeks 55.2 ± 2.3,
58.5 ± 1.6
CRP, TNF-
α, IL-6
Banaszewska
et al. [127]
2007 24/24 Poland/polycystic ovary syndrome Simvastatin+OCP 12 weeks 24 ± 3.5,
23.8 ± 3.7
CRP
Cueto-
Manzano
et a.l.
[128]
2013 76/76 Mexico/continuous ambulatory peritoneal
dialysis (CAPD).
Pravastatin 20mg/day 8 weeks 55.5 ± 10.7,
53.4 ± 13.8
CRP
(continued on next page)
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infarction. In addition, atorvastatin use immediately after an athero-
sclerotic ischemic stroke attenuated the immune-inflammatory activa-
tion in an acute phase of stroke [10]. In a meta-analysis conducted by
Tuttolomondo et al. [11], statin use in patients with chronic heart
failure significantly decreased high-sensitivity CRP (hs-CRP) and so-
luble vascular cell adhesion molecule-1, though did not affect inter-
leukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels. In a sys-
tematic review by Balk et al. [12], statin use decreased CRP levels, not
in a dose-response manner. Discrepancies in current evidences may be
related to the differences in study design, characteristics of study po-
pulations and comorbid conditions, dosage and type of statin used and
statin duration of use.
In this study, we aimed to systematically review and quantify the
effect of statin use on inflammatory markers among patients with MetS
and related disorders in randomized controlled trials (RCTs).
2. Materials and methods
2.1. Search strategy and study selection
To identify RCTs reporting the effects of statin use on inflammatory
markers, two independent authors (O-RT and MA) electronically con-
ducted the searches in PubMed, EMBASE, Web of Science databases,
Cochrane Library, and www.clinicaltrial.gov for ongoing projects
through April 2018. The keywords used for database search were; pa-
tients, including "MetS" and related disorders with metabolic diseases.
These related disorders consisted of "acute coronary syndromes" or
"coronary artery disease" or "CVD" or "diabetic" or "T1DM" or "T2DM" or
"overweight" or "obese" or "chronic kidney disease" or "end-stage renal
disease" or "dialysis" or "heart failure" or "myocardial infarction" or
"atherosclerotic" or "hypercholesterolemic" or "hypertension" or "high
blood pressure" or "dyslipidemia" or "hyperlipidemia" or "polycystic
ovary syndrome" or "stable angina or "unstable angina" or "diabetic
nephropathy" or "obesity or "stable atherosclerotic plaques" or "ather-
osclerotic", intervention, including "statins" or "rosuvastatin" or "ator-
vastatin" or "pravastatin" or "simvastatin" or "fluvastatin" or "cer-
ivastatin" or "lovastatin" and "supplementation" or "intake", and
outcomes, including "CRP" or "TNF-α" or "IL-6" or "IL-1". To avoid
missing any related study, authors checked reference lists of eligible
articles as an additional search. Searches were limited to RCTs pub-
lished in English.
2.2. Inclusion and exclusion criteria
Studies with the following inclusion criteria were included in this
meta-analysis: RCTs conducted on human, provided proper data for the
Table 1 (continued)
First Author Publication year Sample size
(control/
intervention)
Country/Population Intervention (name and daily
dose)
Duration Age (control,
intervention)
Presented
data
Wagner et al.
[129]
2011 71/72 Spain/type 2 diabetes Atorvastatin 10mg/day 12 weeks 57 ± 9 CRP, TNF-
α
Dogra et al.
[130]
2004 16/16 Australia/type 1 diabetes mellitus patients Atorvastatin 40mg/day 6 weeks 46.6 ± 13.0 CRP
Moohebati
et al. [131]
2010 51/51 Iran/who were not originally taking lipid
lowering agents
Simvastatin (40mg/day) 4 weeks 44.18 ± 12.07,
46.00 ± 14.83
CRP
Bays et al.
(2002)
[132]
2002 91/85 Ohio/subjects with mixed hyperlipidemia Simvastatin 40mg/day 6 weeks 52 CRP, IL-6
Bays et al.
(2004)
[133]
2004 148/622 USA+multicenter/hypercholesterolemic
patients
Simvastatin 80mg/day 12 weeks 56 ± 10.8,
54.9 ± 11.2
CRP
Farnier et al.
[134]
2006 60/179 Spain/patients with mixed hyperlipidemia Ezetimibe/Simvastatin 10/
20mg
12 weeks 53.7 ± 11.0,
55.0 ± 10.7
CRP
Goldberg et al.
[135]
2004 52/204 USA+multicenter/hypercholesterolemia Simvastatin 80mg/day 12 weeks 54.69, CRP
Lu et al. [136] 2004 23/23 Multicenter/hypercholesterolemia Rosuvastatin 10mg/day 6 weeks 59.8 ± 11.8,
62.8 ± 11.2
CRP
Tousoulis et al.
(2007)
[120]
2007 13/15 Greece/type 2 diabetes mellitus Atorvastatin-treated (10mg/
day)
4 weeks 60.9 ± 3.1,
58.1 ± 2.6
CRP, TNF-
α, IL-6
Tan et al.
[137]
2002 41/39 Hong Kong/patients with diabetes Atorvastatin (10mg/day) 3 months 55.0 ± 8.1 CRP
Strom et al.
[138]
2012 44/45 Germany/type 1 diabetes and detectable
islet autoantibodies
Aorvastatin (80mg/day) 3 months 0.36 ± 0.42,
0.53 ± 0.39
CRP
Ridker et al.
[19]
2001 2834/2885 Texas/who had average levels of total and
LDL cholesterol
Lovastatin (20mg/day) 12 weeks Men 45 to 73
years old and
women 55 to 73
years old
CRP
Rudofsky et al.
[139]
2012 9/10 Germany/type 2 diabetes Simvastatin 80mg 8 weeks 64 ± 9,
56 ± 10
CRP, IL-6
Vernaglione
et al. [140]
2004 17/16 Italy/hemodialysis Atorvastatin (10mg/day) 6 months 65.47 ± 10.22,
65.19 ± 11.79
CRP
Almquist et al.
[141]
2013 21/21 Sweden/diabetes mellitus Simvastatin was 40mg/day 10 weeks 64 ± 7 TNF-α
Folkeringa
et al. [142]
2010 71/71 Netherlands/hypertension Rosuvastatin 20mg/day 6 months 63 ± 10,
63 ± 11
CRP
CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; IL-6, interlokin-6; IL-1, interlokin-1.
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mean changes of CRP, TNF-α, IL-6, and IL-1 over time with standard
deviation (SD) for both intervention and placebo groups, RCTs con-
ducted among patients with MetS and other related disorders. Other
studies including animal experiments, in vitro studies, observational
studies, study protocols without findings, or congress abstracts without
full texts, non- placebo-controlled trials were excluded from our meta-
analysis.
2.3. Data extraction and quality assessment
Two authors (O-RT and MA) independently extracted data from
each selected RCTs using a standard abstraction excel sheet. The ex-
tracted data included the name of first author, year of publication,
study setting, the characteristics of participants, study design, sample
size in both treatment and placebo groups, dosage of statin, duration of
statin, type of disease, and outcomes of interest including the mean and
SD for CRP, TNF-α, IL-6, and IL-1. The methodological quality of the
selected RCTs was evaluated by two independent investigators (MA and
RT) using the Cochrane Collaboration risk of bias tool. Also, Jadad's
quality scales were determined to assess internal validity of clinical
trials. The Cochrane Collaboration risk of bias tool used the following
criteria for quality assessment: "randomization generation, allocation
concealment, blinding of participants and outcome assessment, in-
complete outcome data, and selective outcome reporting, and other
sources of bias". Jadad's total score lower than 3 represented the low
quality and ≥3 showed the high quality of included trials reporting.
Any disagreement between authors was resolved by discussion and final
consensus between authors or a third author (ZA) approved the find-
ings.
2.4. Data synthesis and statistical analysis
The mean differences with SD of inflammatory markers between
intervention and placebo groups were used to pool data. The standar-
dized mean differences (SMDs) with corresponding 95% CI were cal-
culated as effect sizes using the fixed effect model (with inverse var-
iance method) or random effect model (Dersimonian–Lairdmethod
method). Heterogeneity was assessed using Cochran’s Q test and I-
square (I2) test with an I2> 50% (P < 0.05) was considered to be a
significant heterogeneity. Sensitivity analyses were conducted using
Fig. 2. A–D. Random effects meta analysis of randomized controlled trials that examined the effect of statins intake on inflammatory markers including (A1) strata
cardiovascular for CRP levels, (A2) strata other disease for CRP levels, (A3) strata diabetic for CRP levels (B) for TNF-α, (C) for IL-6, (D) for IL-1 in intervention and
control groups with 95% CI.
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leave-one-out method to determine the effect of each individual trial on
reliability of the overall pooled SMDs. Further, subgroup analyses were
carried out to determine the source of heterogeneity according to the
potential moderator variables. The subgroup analyses were conducted
according to the following variables: dosage of statins (< 40 vs. ≥40
mg/day), type of statin used (rosuvastatin vs. atorvastatin vs. simvas-
tatin vs. statins plus other drugs vs. statins plus nutrients vs. other
statins), type of disease (CVD vs. diabetic vs. other disease), duration of
study (≤8 vs.> 8 weeks), and Jadad's overall scores (high risk vs. low
risk). Egger's regression tests and funnel plot symmetry tests were used
to evaluate any possible publication bias in our meta-analysis. All sta-
tistical analyses were conducted using STATA software version 12.0
(Stata Corp., College Station, TX) and RevMan V.5.3 software
(Cochrane Collaboration, Oxford, UK). P < 0.05 was considered sta-
tistically significant.
3. Results
Overall, 113 articles, out of 2740 citations, met our inclusion cri-
teria. One hundred thirteen articles included 19,644 participants which
were randomly assigned to 10,460 individuals in treatment group and
9190 in placebo group. One hundred forty-seven RCTs have reported
the impact of statin use on CRP, 56 RCTs on TNF-α, 68 RCTs on IL-6,
and 15 RCTs on IL-1 levels. The step by step screening process has been
illustrated in Fig. 1. The sample size varied from 13 to 5719 individuals
among included articles in our meta-analysis. Dosage of statin use
ranged from 0.3 to 80mg/day. Duration of statin use ranged from 4
weeks to 3 years. The selected RCTs were published between 2001 and
2017. Diagnosis of MetS in the included studies was conducted based on
the criteria of the NCEP-Adult Treatment Panel III [13–18]. The de-
tailed characteristics of included RCTs have been summarized in
Table 1.
3.1. The association between statin use and inflammatory markers
Forest plots demonstrating the effects of statin use on inflammatory
markers are shown in Fig. 2. Our results showed that statin use in pa-
tients with MetS and related disorders significantly decreased CRP
(SMD= -0.97; 95% CI, -1.10, -0.85; P < 0.001; I2: 95.1%), TNF-α
(SMD= -1.88; 95% CI, -2.40, -1.38; P < 0.001; I2: 97.2%), IL-6
(SMD= -1.67; 95% CI, -1.98, -1.34; P < 0.001; I2: 96.5%), and IL-1
levels (SMD= -8.35; 95% CI, -10.49, -6.22; P < 0.001; I2: 98.4%).
Pooled effect sizes, calculated based on the baseline and end of trial
information in treatment and placebo groups are summarized in
Table 2.
Fig. 2. (continued)
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3.2. Sensitivity/subgroup analyses
We did not find any statistical significant difference between pre-
and post-sensitivity pooled SMDs for all inflammatory markers.
However, the lower and higher pooled SMDs for CRP were -0.99 (95%
CI: -1.13, - 0.84) after excluding Ridkar et al. [19] study and -0.92 (95%
CI: -1.04, -0.80) after removing Sola et al. [20] study. For TNF-α, the
lower pooled SMDs in was -2.01 (95% CI: -2.51, -1.51) after excluding
Hu Y et al. [21] study and the higher was -1.64 (95% CI: -2.13, -1.15)
after excluding Krysiak (a) et al. [22] study. The lower and higher
pooled SMDs for IL-6 were -1.74 (95% CI: -2.10, -1.38) after excluding
Kinlay et al. [23] study and -1.50 (95% CI: -1.81, -1.20) after removing
Krysiak (a) et al. [24] study, respectively. For IL-1, the lower pooled
SMD in the sensitivity analysis was -9.01 (95% CI: -11.40, -6.62) after
excluding Jialal et al. [25] study and the higher was -7.13 (95% CI:
-9.29, -5.33) after removing Krysiak (a) et al. [22] study (Table 3).
Following subgroup analyses, heterogeneity was changed among
some of the strata of subgroups, however there was no significant dif-
ference between before and after subgroup analysis. The detailed
findings of subgroups analyses are presented in Table 4.
3.3. Publication bias and quality assessment
As presented in Fig. 3, there was potential publication bias for in-
flammatory markers including CRP (B=-1.84, P=0.001), TNF-α (B=
-4.02, P=0.04), IL-6 (B=-4.73, P=0.001), and IL-1 (B=-12.57,
P=0.001). Non-parametric method (Duval and Tweedie) was used to
compute the results of censored articles. Pooled effect sizes for in-
flammatory markers did not significantly change after Duval and
Tweedie test.
The pooled SMD before and after including censored articles were
-0.97 (95% CI, -1.10, -0.84) and -1.21 (95% CI, -1.34, -1.07) for CRP,
-1.88 (95% CI, -2.40, -1.38) and -2.60 (95% CI, -3.19, -2.01) for TNF-α
levels, respectively. Pooled SMD for IL-6 levels before including cen-
sored articles was -1.67 (95% CI, -1.98, -1.34) compared with -2.35
(95% CI, -2.79, -1.91) after including censored articles. For IL-1, SMD
before including articles was -8.35 (95% CI, -10.49, -6.21) which
changed to -8.35 (95% CI, -10.48, -6.22) after including censored ar-
ticles.
The methodological qualities of RCTs was assessed using Cochrane
Collaboration risk of bias tool and Jadad’s overall scores and are
Fig. 2. (continued)
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summarized in Table 5.
4. Discussion
To our best knowledge, this is the first systematic review and meta-
analyses of RCTs evaluating the effect of statin use on inflammatory
markers among patients with MetS and related disorders. Our meta-
analysis (including 113 RCTs and 19,644 patients) showed the bene-
ficial impact of statin use on reducing inflammatory markers in patients
suffering from MetS and related disorders. Increased inflammatory
markers are one of the main pathophysiological causes of diseases re-
lated to metabolic disorders, which include different chronic, condi-
tions such as obesity, T2DM, CVD, stroke, fatty liver, and other meta-
bolic diseases. Therefore, due to similar metabolic status, we included a
broad range of chronic diseases in the current meta-analysis. However,
the effectiveness of statin use might vary with the type of metabolic
abnormalities. To address this limitation, we have conducted subgroup
analysis based on the type of metabolic diseases (e.g. cardiovascular vs.
diabetes vs. other related disorders).
MetS and other related disorders especially heart failure are con-
sidered as inflammatory diseases [26,27]. Different inflammatory
markers including IL-6 and TNF-α may contribute to endothelial dys-
function, cardiac myocyte apoptosis, structural deterioration and left
ventricular dysfunction [28,29]. Furthermore, hs-CRP is one of the
common inflammatory markers to assess inflammation. It is an in-
dependent predictor for MetS prognosis and other related disorders,
therefore, it can provide additional prognostic information for the risk
stratification and treatment of patients with CVD [30]. In a meta-ana-
lysis conducted by Zhang et al, statin use significantly decreased hs-CRP
and soluble vascular cell adhesion molecule-1 in patients with chronic
heart failure, though it did not influence IL-6 and TNF-α [11]. Further,
in a systematic review assessing the effect of different statins, they were
Fig. 2. (continued)
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effective to reduce CRP levels, though dose-independent [12]. In an-
other meta-analysis, statin use elevated left ventricular ejection fraction
and reduced hospitalization due to worsening heart failure. Using
atorvastatin, all-cause mortality also significantly decreased [31].
Among statin pre-treated patients, the risk of increasing CRP post-
operatively was significantly lower [32]. However, in another meta-
analysis conducted by Artola et al, there was no significant impact of
statin use on serum levels of hs-CRP in patients with systemic lupus
erythematosus [33]. Discrepant results might be related to differences
in study design, characteristics of study populations, dosage, type and
duration of statin use.
Previous studies have documented the drug-specific effects of statins
[34]. Atorvastatin may reduce hs-CRP-induced inflammatory response
by inhibiting nuclear factor-kB pathway [35]. Statin use can also de-
crease stimulating activator protein-1 (AP-1), a transcription factor
which in turn might decrease inflammatory markers [36]. Further, the
Rho-Rho kinase pathway, which is a negative regulator of endothelial
nitric oxide synthase (eNOS) activity, is usually activated in in-
flammatory status and might reduce nitric oxide (NO) availability.
Statin use causes a remarkable increase in eNOS activity by decreasing
prenylation of Rho [37]. Furthermore, post-translational activation of
eNOS involves phosphatidyl inositol 3-kinase (PI3K) and the serine/
threonine kinase, Akt (PI3K-Akt) signaling pathway, which is the other
mechanism by which statin use might decrease inflammation [38].
There are several strengths for this study. Large numbers of studies
included in this meta-analysis and longer period of intervention in in-
cluded RCTs have increased the value of this meta-analysis. All in-
cluded studies were placebo-controlled randomized trials with accep-
table methodological quality. Further, we relied on independent
judgment in which different reviewers independently performed the
systematic review process. The current meta-analysis had a few lim-
itations. Different doses of statins were used for intervention in the
included RCTs. Considerable heterogeneity across studies made us to
interpret our results cautiously.
In summary, our meta-analysis demonstrated that statin use in pa-
tients with MetS and related disorders appeared to significantly de-
crease inflammatory markers, such as CRP, TNF-α, IL-6 and IL-1 levels.
Table 2
Standardized mean difference of related indictors between the intervention and placebo groups.
Variables Number of study Standardized mean difference CI 95% P-value Heterogeneity
I2 (%) Q P- value heterogeneity
CRP Intervention group (after vs. before) 146 −0.51 −0.62, -0.41 < 0.001 93.5 2216.18 < 0.001
Placebo group (after vs. before) 146 0.06 −0.03, 0.14 0.200 88.6 1270.14 < 0.001
Change intervention group vs. placebo group 147 −0.97 −1.10, -0.84 < 0.001 95.1 2966.70 < 0.001
TNF-α Intervention group (after vs. before) 56 −1.11 −1.57, -0.65 < 0.001 97.1 1920.65 < 0.001
Placebo group (after vs. before) 56 0.03 −0.17, 0.24 0.750 87.4 436.16 < 0.001
Change intervention group vs. placebo group 56 −1.88 −2.40, -1.38 < 0.001 97.2 1931.96 < 0.001
IL-6 Intervention group (after vs. before) 65 −1.05 −1.38, -0.73 < 0.001 96.8 1974.22 < 0.001
Placebo group (after vs. before) 65 −0.20 −0.45, 0.06 0.129 94.3 1130.47 < 0.001
Change intervention group vs. placebo group 69 −1.67 −1.98, -1.34 < 0.001 96.5 1926.58 < 0.001
IL-1 Intervention group (after vs. before) 15 −4.09 −5.41, -2.75 < 0.001 97.8 628.66 < 0.001
Placebo group (after vs. before) 15 −0.16 −0.30, -0.03 0.019 9.0 15.38 0.352
Change intervention group vs. placebo group 15 −8.35 −10.49, -6.21 < 0.001 98.4 881.22 < 0.001
SMD, standardized mean differences; CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; IL-6, interlokin-6; IL-1, interlokin-1.
Table 3
The association between statin use and inflammatory markers followed by sensitivity analysis.
Variables Pre-sensitivity analysis Upper & lower of effect size Post-sensitivity analysis
No. of studies included Pooled SMD
(random effect)
95% CI Pooled SMD
(random effect)
95% CI Excluded
studies
CRP 147 −0.97 −1.10, -0.84 Upper −0.92 −1.04, -0.80 Sola (2005)
Lower −0.99 −1.13, -0.84 Ridker (2001)
TNF-α 56 −1.88 −2.40, -1.38 Upper −1.64 −2.13, -1.15 Krysiak(a) (2010)
Lower −2.01 −2.51, -1.51 Hu Y (2009)
IL-6 69 −1.67 −1.98, -1.34 Upper −1.50 −1.81, -1.20 Krysiak(a) (2010)
Lower −1.74 −2.10, -1.38 Kinlay (2003)
IL-1 15 −8.35 −10.49, -6.21 Upper −7.13 −9.29, -5.33 Krysiak(a) (2010)
Lower −9.01 −11.40, -6.62 Jialal (2007)
CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; IL-6, interlokin-6; IL-1, interlokin-1; SMD, standardized mean differences.
R. Tabrizi et al. Pharmacological Research 141 (2019) 85–103
96
Table 4
The association between statin use and inflammatory markers following subgroup analysis.
Variables K* I2 (%) Q test SMD (95% CI) P-value
CRP
Total 147 95.1 2966.70 −0.97 (-1.10, -0.85) < 0.001
Dosage of statins (mg/day)
< 40 93 95.1 1860.83 −0.96 (-1.12, -0.79) < 0.001
≥40 54 94.9 1044.44 −0.99 (-1.22, -0.78) < 0.001
Type of intervention
Rosuvastatin 20 93.9 311.31 −0.88 (-1.14, -0.62) < 0.001
Atorvastatin 61 96.0 1482.42 −1.14 (-1.41, -0.86) < 0.001
Statins plus other drugs 12 95.7 255.89 −1.57 (-2.21, -0.92) < 0.001
Other statins 22 96.5 599.23 −0.97 (-1.37, -0.57) < 0.001
Simvastatin 29 88.8 249.38 −0.68 (-0.93, -0.43) < 0.001
Statins plus nutrient 3 3.5 2.07 −0.65 (-0.92, -0.38) < 0.001
Type of disease
Cardiovascular 82 95.5 1812.29 −0.81(-0.96, -0.66) < 0.001
Diabetic 28 94.8 518.16 −1.35 (-1.80, -0.91) < 0.001
Other 37 93.9 588.16 −1.21 (-1.61, -0.81) < 0.001
Duration of study
> 8 weeks 71 96.2 1836.25 −1.07 (-1.24, -0.89) < 0.001
≤8 weeks 76 93.4 1130.07 −0.90 (-1.14, -0.69) < 0.001
Jadad's overall scores
High risk 31 94.3 529.92 −0.87 (-1.27, -0.47) < 0.001
Low risk 115 95.3 2436.70 −0.40 (-0.73, -0.07) < 0.001
TNF-α
Total 56 97.2 1931.96 −1.88 (-2.40, -1.38) < 0.001
Dosage of statins (mg/day)
< 40 32 96.4 857.80 −1.42 (-1.99, -0.86) < 0.001
≥40 24 97.7 1002.45 −2.63 (-3.60, -1.68) < 0.001
Type of intervention
Rosuvastatin 6 92.6 67.60 −1.72 (-2.72, -0.71) 0.001
Atorvastatin 23 97.8 985.95 −3.04 (-4.05, -2.04) < 0.001
Statins plus other drugs 5 97.2 141.90 −1.89 (-3.59, -0.19) 0.030
Other statins 4 97.4 114.39 −2.21 (-3.61, -0.81) 0.002
Simvastatin 15 94.9 276.70 −0.68 (-1.48, 0.11) 0.093
Statins plus nutrient 3 60.4 5.06 −0.09 (-0.74, 0.55) 0.775
Type of disease
Cardiovascular 27 97.1 902.40 −2.25 (-2.94, -1.57) < 0.001
Diabetic 12 95.5 243.67 −0.03 (-0.90, 0.82) 0.93
Other 17 97.2 562.88 −2.78 (-3.91, -1.64) < 0.001
Duration of study
> 8 weeks 27 97.8 1188.16 −1.60 (-2.38, -0.82) < 0.001
≤8 weeks 29 96.2 740.97 −2.15 (-2.82, -1.47) < 0.001
Jadad's overall scores
High risk 8 95.0 139.81 −0.89 (-1.70, -0.10) 0.02
Low risk 48 97.3 1762.52 −2.08 (-2.68, -1.47) < 0.001
IL-6
Total 69 96.5 1926.58 −1.67 (-1.98, -1.34) < 0.001
Dosage of statins (mg/day)
< 40 46 95.1 918.26 −1.25 (-1.65, -0.85) < 0.001
≥40 23 97.7 939.86 −2.60 (-3.23, -1.98) < 0.001
Type of intervention
Rosuvastatin 7 80.3 30.52 −1.17 (-1.55, -0.78) < 0.001
Atorvastatin 29 97.6 1172.66 −2.25 (-2.87, -1.62) < 0.001
Statins plus other drugs 3 98.3 114.57 −6.12 (-12.09, -0.15) 0.045
Other statins 7 93.4 91.17 −4.67 (-1.41, 0.07) 0.076
Simvastatin 21 93.8 323.59 −1.15 (-1.67, -0.64) 0.016
Statins plus nutrient 2 0.0 0.11 −0.73 (-1.32, -0.14) < 0.001
Type of disease
Cardiovascular 40 96.8 1229.95 −1.67 (-2.07, -1.28) < 0.001
Diabetic 9 88.5 69.54 −2.0 (-2.71, -1.29) < 0.001
Other 20 95.1 387.60 −1.48 (-2.16, -0.78) < 0.001
Duration of study
> 8 weeks 23 97.5 894.36 −1.95 (-2.57, -1.33) < 0.001
≤8 weeks 46 95.3 965.30 −1.56 (-1.96, -1.17) < 0.001
Jadad's overall scores
High risk 16 95.8 359.59 −1.36 (-2.07, -0.64) < 0.001
Low risk 53 96.7 1564.45 −1.77 (-2.14, -1.40) < 0.001
IL-1
Total 15 98.4 881.22 −8.35 (-10.48, -6.22) < 0.001
Dosage of statins (mg/day)
< 40 3 98.5 135.45 −5.67 (-9.76, -1.58) 0.007
≥40 12 98.4 703.17 −9.09 (-11.86, -6.32) < 0.001
Type of intervention
Rosuvastatin – – – – –
Atorvastatin 6 98.6 345.42 −12.69 (-18.62, -6.76) < 0.001
(continued on next page)
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Table 4 (continued)
Variables K* I2 (%) Q test SMD (95% CI) P-value
Statins plus other drugs 4 96.1 76.00 −7.20 (-11.33, -3.07) 0.001
Other statins
Simvastatin 5 97.9 187.60 −4.22 (-6.44, -2.00) 0.001
Statins plus nutrient – – – – –
Type of disease
Cardiovascular 7 98.3 358.47 −9.18 (-13.22, -5.13) < 0.001
Diabetic 1 – – −0.12 (-0.66, 0.43) 0.67
Other 7 98.6 428.78 −8.99 (-12.76, -5.22) < 0.001
Duration of study
> 8 weeks 6 98.9 450.73 −11.20 (-15.98, -6.43) < 0.001
≤8 weeks 9 98.1 428.88 −6.67 (-9.25, -4.09) < 0.001
Jadad's overall scores
High risk – – – – –
Low risk 15 98.4 881.22 −8.35 (-10.49, -6.22) < 0.001
* K, Number of SMD Included; CRP, C-reactive protein; TNF-α, tumor necrosis factor alpha; IL-6, interlokin-6; IL-1, interlokin-1; SMD, standardized mean differences
Fig. 3. A–D. Begg’s funnel plot for assessing the publication bias (A) CRP, (B) for TNF-α, (C) for IL-6, and (D) for IL-1.
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Table 5
Quality assessment of included clinical trials using Cochrane's risk of bias tool and Jadad’s scale.
First Author Cochrane's risk of bias tool Jadad's
scores
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of participants
and personnel
(performance bias)
Blinding of outcome
assessment
(detection bias)
Incomplete
outcome
Selective
reporting
other
sources of
bias
Jiao et al Low risk Unclear risk Low risk Unclear risk Low risk Low risk Low risk 4
Wang et al Low risk Low risk Low risk Low risk High risk Low risk Low risk 3
Kinlay et al Low risk Low risk Low risk Low risk Low risk Low risk High risk 4
Patti et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 4
Lewandowski et al Low risk Unclear risk High risk High risk Low risk Low risk Low risk 2
Correia et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Low risk 3
Dohi et al Low risk Low risk High risk High risk Unclear risk Low risk Low risk 3
Yun et al (2009) Low risk Low risk High risk High risk Low risk Low risk Unclear risk 3
Yun et al (2011) Low risk Low risk High risk High risk Low risk Low risk Unclear risk 3
Macin et al Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk 4
Vasilieva et al Low risk Low risk High risk High risk Low risk Low risk Unclear risk 3
Wassmann et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 5
Li et al (2007) Low risk Unclear risk Low risk Low risk Unclear risk Low risk Unclear risk 3
Li et al (2005) Low risk Unclear risk High risk High risk Unclear risk Low risk Unclear risk 2
Sawara Y Low risk Low risk Low risk Low risk Low risk Low risk High risk 4
Fassett et al Low risk Unclear risk High risk High risk High risk Low risk Unclear risk 2
Verma et al Low risk Unclear risk High risk High risk Unclear risk Low risk High risk 2
Jo et al Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk 5
Marschang et al High risk High risk Low risk Low risk Low risk Low risk High risk 2
Chan et al Low risk Unclear risk High risk High risk Low risk Low risk Low risk 2
Suzuki et al High risk High risk High risk High risk Low risk Low risk Unclear risk 1
Azar et al Unclear risk Unclear risk High risk High risk Low risk Low risk High risk 2
Karaca et al Unclear risk Unclear risk High risk High risk Low risk Low risk Unclear risk 2
Abe et al Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Dornbrook-
Lavender et al
Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Sezer et al Low risk Unclear risk High risk High risk Unclear risk Low risk Unclear risk 2
Arabul et al Low risk Unclear risk High risk High risk Low risk Low risk Unclear risk 2
Abulhul et al Low risk Unclear risk High risk High risk Unclear risk Low risk Unclear risk 2
Kirmizis et al Low risk Unclear risk High risk High risk Low risk Low risk Low risk 2
Chang et al Low risk Low risk High risk High risk Unclear risk Low risk Unclear risk 3
Burmeister et al Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk 4
Ichihara et al Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk 3
Ge et al Low risk Unclear risk Low risk Low risk Low risk Low risk Unclear risk 4
Yamagami et al Unclear risk Unclear risk Low risk Low risk Unclear risk Low risk Low risk 3
Koh et al (2004) Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk 3
Koh (2008) Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk 3
Koh et al (2009) Low risk Unclear risk Low risk High risk Low risk Low risk Low risk 3
Koh et al (2009) Low risk Unclear risk Low risk High risk Low risk Low risk Low risk 3
Koh et al (2010) Low risk Unclear risk Low risk High risk Low risk Low risk Low risk 3
Koh et al (2015) Low risk Unclear risk Low risk High risk Low risk Low risk Low risk 3
Nilsson et al Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk 4
Ascer et al Low risk Low risk High risk High risk Low risk Low risk High risk 3
Kuklinska et al Low risk Low risk High risk High risk Low risk Low risk High risk 3
McMurray et al Low risk Low risk Low risk High risk Low risk Low risk High risk 5
Zhang et al Low risk Low risk High risk High risk Unclear risk Low risk Low risk 3
Singh et al Low risk Low risk Low risk Low risk Unclear risk Low risk Low risk 3
Oguz et al Low risk Low risk High risk High risk Unclear risk Low risk Low risk 3
Devaraj et al Low risk Low risk Low risk Low risk Unclear risk Low risk Low risk 3
Krysiak et al Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk 4
Nafasi et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 4
Chan et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Low risk 4
Puurunen et al Low risk Low risk Low risk Low risk High risk Low risk Unclear risk 5
Sathyapalan et al Low risk Low risk Low risk Low risk High risk Low risk Low risk 3
Raja-Khan et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 3
Guo et al Low risk Unclear risk High risk High risk High risk Low risk High risk 2
Lunder et al Low risk Unclear risk Low risk Low risk Low risk Low risk Low risk 4
Fegan et al Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk 4
Konduracka et al Low risk Unclear risk High risk High risk Low risk Low risk High risk 1
van de Ree et al Low risk Low risk Low risk Low risk Low risk Low risk High risk 3
Economides et al Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk 5
Jialal et al Low risk Low risk Low risk Low risk Unclear risk Low risk Low risk 3
Ghanim et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Low risk 3
Joy et al Low risk Low risk High risk High risk Low risk Low risk High risk 2
luo et al Low risk Unclear risk Low risk High risk Unclear risk Low risk High risk 3
Goicoechea et al Low risk Low risk High risk High risk High risk Low risk High risk 3
Strazhesko et al Low risk Low risk High risk High risk Low risk Low risk Unclear risk 3
Sola et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 5
Li et al Low risk Unclear risk High risk High risk Low risk Low risk High risk 2
Doo et al High risk High risk High risk High risk Low risk Low risk High risk 1
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Table 5 (continued)
First Author Cochrane's risk of bias tool Jadad's
scores
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of participants
and personnel
(performance bias)
Blinding of outcome
assessment
(detection bias)
Incomplete
outcome
Selective
reporting
other
sources of
bias
Gruzdeva et al High risk High risk High risk High risk Low risk Low risk High risk 1
Andreou et al Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk 5
Nakagom et al High risk High risk Low risk Low risk High risk Low risk High risk 2
Doh et al Low risk Unclear risk High risk High risk Unclear risk Low risk Low risk 3
Gonalves et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Unclear risk 4
Ostadal et al Low risk Low risk High risk High risk Unclear risk Low risk Unclear risk 2
Link et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 5
Yang et al Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Kishimoto et al Low risk Low risk High risk High risk Low risk Low risk High risk 3
Krysiak et al Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Stefanadi et al Low risk Unclear risk Unclear risk Unclear risk Low risk Low risk Low risk 2
Pereira et al High risk High risk High risk High risk Unclear risk Low risk High risk 1
Tousoulis et al Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Nawawi et al Low risk Low risk Low risk Low risk Unclear risk Low risk High risk 4
Gomez-Garcla et al Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Tousoulis et al
(2005)
Low risk Low risk High risk High risk Low risk Low risk Low risk 3
Tousoulis et al
(2005)
Low risk Low risk High risk High risk Unclear risk Low risk Unclear risk 3
Tousoulis et al
(2006)
Low risk Low risk High risk High risk Unclear risk Low risk Unclear risk 3
Usharani et al Low risk Low risk Low risk Low risk Unclear risk Low risk Low risk 5
KrysiaK et al High risk High risk Low risk Low risk Unclear risk Low risk Unclear risk 2
Xie et al Low risk Low risk High risk High risk High risk Low risk Low risk 3
Koh et al Low risk Unclear risk Low risk High risk Low risk Low risk Low risk 3
Sola et al Low risk Low risk Low risk Low risk High risk Low risk Low risk 4
Zhao et al Low risk Low risk High risk High risk Unclear risk Low risk Low risk 3
Huptas et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Low risk 4
Hu et al Low risk Low risk Low risk High risk Unclear risk Low risk High risk 4
Banaszewska et al Low risk Low risk High risk High risk Unclear risk Low risk Unclear risk 3
Cueto-Manzano
et al
Low risk Low risk Low risk Low risk Low risk Low risk Low risk 5
Wagner et al Low risk Low risk High risk High risk Low risk Low risk Low risk 4
Dogra et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 5
Moohebati et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 4
Bays et al(2002) Low risk Unclear risk Low risk Low risk Unclear risk Low risk High risk 3
Bays et al (2004) Low risk Low risk Low risk Low risk High risk Low risk High risk 4
Farnier et al Low risk Low risk Low risk Low risk Unclear risk Low risk High risk 4
Goldberg et al Low risk Low risk Low risk Low risk High risk Low risk High risk 4
Lu et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Low risk 4
Tousoulis et al
(2007)
Low risk Unclear risk Low risk High risk Unclear risk Low risk Unclear risk 3
Tan et al Low risk Unclear risk Low risk Low risk High risk Low risk Unclear risk 3
Strom et al Low risk Low risk High risk High risk Unclear risk Low risk Unclear risk 3
Ridker et al Low risk Unclear risk Low risk Low risk Unclear risk Low risk Unclear risk 4
Rudofsky et al Low risk Low risk Low risk Low risk Low risk Low risk Low risk 4
Vernaglione et al Low risk Low risk High risk High risk Unclear risk Low risk Low risk 3
Almquist et al Low risk Low risk Low risk Low risk Low risk Low risk Unclear risk 5
Folkeringa et al Low risk Unclear risk High risk Low risk Low risk Low risk Low risk 3
R. Tabrizi et al. Pharmacological Research 141 (2019) 85–103
100
Acknowledgement
The present study was supported by a grant from the Vice-chan-
cellor for Research, SUMS, Shiraz, and Iran.
References
[1] P. Libby, Y. Okamoto, V.Z. Rocha, E. Folco, Inflammation in atherosclerosis:
transition from theory to practice, Circ. J. 74 (2010) 213–220.
[2] A.S. Antonopoulos, M. Margaritis, R. Lee, K. Channon, C. Antoniades, Statins as
anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons
from the recent clinical trials, Curr. Pharm. Des. 18 (2012) 1519–1530.
[3] C. Liu, X. Feng, Q. Li, Y. Wang, M. Hua, Adiponectin, TNF-alpha and inflammatory
cytokines and risk of type 2 diabetes: a systematic review and meta-analysis,
Cytokine 86 (2016) 100–109.
[4] G. Yuan, L. Zhou, J. Tang, Y. Yang, W. Gu, F. Li, et al., Serum CRP levels are
equally elevated in newly diagnosed type 2 diabetes and impaired glucose toler-
ance and related to adiponectin levels and insulin sensitivity, Diabetes Res. Clin.
Pract. 72 (2006) 244–250.
[5] S. Devaraj, N. Torok, M.R. Dasu, D. Samols, I. Jialal, Adiponectin decreases C-
reactive protein synthesis and secretion from endothelial cells: evidence for an
adipose tissue-vascular loop, Arterioscler. Thromb. Vasc. Biol. 28 (2008)
1368–1374.
[6] Executive Summary of The Third Report of The National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High
Blood Cholesterol In Adults (Adult Treatment Panel III), Jama 285 (2001)
2486–2497.
[7] S.N. Magge, N. Stettler, D. Koren, L.E. Levitt Katz, P.R. Gallagher, E.R. Mohler
3rdet al., Adiponectin is associated with favorable lipoprotein profile, independent
of BMI and insulin resistance, in adolescents, J. Clin. Endocrinol. Metab. 96 (2011)
1549–1554.
[8] S.H. Han, M.J. Quon, J.A. Kim, K.K. Koh, Adiponectin and cardiovascular disease:
response to therapeutic interventions, J. Am. Coll. Cardiol. 49 (2007) 531–538.
[9] O. Gruzdeva, E. Uchasova, Y. Dyleva, O. Akbasheva, V. Karetnikova, O. Barbarash,
Early effects of treatment low-dose atorvastatin on markers of insulin resistance
and inflammation in patients with myocardial infarction, Front. Pharmacol. 7
(2016) 324.
[10] A. Tuttolomondo, D. Di Raimondo, R. Pecoraro, C. Maida, V. Arnao, V. Della
Corte, et al., Early high-dosage atorvastatin treatment improved serum immune-
inflammatory markers and functional outcome in acute ischemic strokes classified
as large artery atherosclerotic stroke: a randomized trial, Medicine (Baltimore) 95
(2016) e3186.
[11] L. Zhang, S. Zhang, H. Jiang, A. Sun, Y. Wang, Y. Zou, et al., Effects of statin
therapy on inflammatory markers in chronic heart failure: a meta-analysis of
randomized controlled trials, Arch. Med. Res. 41 (2010) 464–471.
[12] E.M. Balk, J. Lau, L.C. Goudas, H.S. Jordan, B. Kupelnick, L.U. Kim, et al., Effects
of statins on nonlipid serum markers associated with cardiovascular disease: a
systematic review, Ann. Intern. Med. 139 (2003) 670–682.
[13] S. Devaraj, D. Siegel, I. Jialal, Simvastatin (40 mg/day), adiponectin levels, and
insulin sensitivity in subjects with the metabolic syndrome, Am. J. Cardiol. 100
(2007) 1397–1399.
[14] R. Krysiak, A. Gdula-Dymek, R. Bachowski, B. Okopien, Pleiotropic effects of
atorvastatin and fenofibrate in metabolic syndrome and different types of pre-
diabetes, Diabetes Care 33 (2010) 2266–2270.
[15] X. Zhang, X. Zeng, L. Dong, X. Zhao, X. Qu, The effects of statins on benign pro-
static hyperplasia in elderly patients with metabolic syndrome, World J. Urol. 33
(2015) 2071–2077.
[16] A. Oguz, M. Uzunlulu, Short term fluvastatin treatment lowers serum asymmetric
dimethylarginine levels in patients with metabolic syndrome, Int. Heart J. 49
(2008) 303–311.
[17] S. Huptas, H.C. Geiss, C. Otto, K.G. Parhofer, Effect of atorvastatin (10 mg/day) on
glucose metabolism in patients with the metabolic syndrome, Am. J. Cardiol. 98
(2006) 66–69.
[18] U. Singh, S. Devaraj, I. Jialal, D. Siegel, Comparison effect of atorvastatin (10
versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with
metabolic syndrome, Am. J. Cardiol. 102 (2008) 321–325.
[19] P.M.R.N. Ridker, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles, A.M. Gotto Jr,
Measurement of C-reactive protein for the targeting of statin therapy in the pri-
mary prevention of acute coronary events, N. Engl. J. Med. 28 (June(344)) (2001)
1959–1965.
[20] S. Sola, M.Q. Mir, B.V. Khan, S. Lerakis, N. Tandon, Atorvastatin improves left
ventricular systolic function and serum markers of inflammation in nonischemic
heart failure, J. Am. Coll. Cardiol. 17 (47) (2006 Jan) 332–337.
[21] Y. Hu, G. Tong, W. Xu, J. Pan, K. Ryan, R. Yang, et al., Anti-inflammatory effects of
simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis,
Diab. Vasc. Dis. Res. 6 (October) (2009) 262–268.
[22] R. Krysiak, B. Okopien, The effect of ezetimibe and simvastatin on monocyte cy-
tokine release in patients with isolated hypercholesterolemia, J. Cardiovasc.
Pharmacol. 57 (2011) 505–512.
[23] S. Kinlay, G.G. Schwartz, A.G. Olsson, N. Rifai, S.J. Leslie, W.J. Sasiela, et al.,
High-dose atorvastatin enhances the decline in inflammatory markers in patients
with acute coronary syndromes in the MIRACL study, Circulation 108 (2003)
1560–1566.
[24] R. Krysiak, A. Gdula-Dymek, R. Bachowski, B. Okopień, Pleiotropic effects of
atorvastatin and fenofibrate in metabolic syndrome and different types of pre-
diabetes, Diabetes Care 33 (2010) 2266–2270.
[25] I. Jialal, E. Miguelino, S.C. Griffen, S. Devaraj, Concomitant reduction of low-
density lipoprotein-cholesterol and biomarkers of inflammation with low-dose
simvastatin therapy in patients with type 1 diabetes, J. Clin. Endocrinol. Metab. 1
(August(92)) (2007) 3136–3140.
[26] S. Adamopoulos, J.T. Parissis, D.T. Kremastinos, A glossary of circulating cyto-
kines in chronic heart failure, Eur. J. Heart Fail. 3 (2001) 517–526.
[27] K. Ma, X. Jin, X. Liang, Q. Zhao, X. Zhang, Inflammatory mediators involved in the
progression of the metabolic syndrome, Diabetes Metab. Res. Rev. 28 (2012)
388–394.
[28] D.J. Pinsky, B. Cai, X. Yang, C. Rodriguez, R.R. Sciacca, P.J. Cannon, The lethal
effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric
oxide synthase antagonism or transforming growth factor beta, J. Clin. Invest. 95
(1995) 677–685.
[29] D.L. Mann, Inflammatory mediators and the failing heart: past, present, and the
foreseeable future, Circ. Res. 91 (2002) 988–998.
[30] W.H. Yin, J.W. Chen, H.L. Jen, M.C. Chiang, W.P. Huang, A.N. Feng, et al.,
Independent prognostic value of elevated high-sensitivity C-reactive protein in
chronic heart failure, Am. Heart J. 147 (2004) 931–938.
[31] M.J. Lipinski, C.A. Cauthen, G.G. Biondi-Zoccai, A. Abbate, B. Vrtovec, B.V. Khan,
et al., Meta-analysis of randomized controlled trials of statins versus placebo in
patients with heart failure, Am. J. Cardiol. 104 (2009) 1708–1716.
[32] J. An, F. Shi, S. Liu, J. Ma, Q. Ma, Preoperative statins as modifiers of cardiac and
inflammatory outcomes following coronary artery bypass graft surgery: a meta-
analysis, Interact. Cardiovasc. Thorac. Surg. 25 (2017) 958–965.
[33] R.T. Artola, C.G. Mihos, O. Santana, Effects of statin therapy in patients with
systemic lupus erythematosus, South. Med. J. 109 (2016) 705–711.
[34] R. Hurks, I.E. Hoefer, A. Vink, G. Pasterkamp, A. Schoneveld, M. Kerver, et al.,
Different effects of commonly prescribed statins on abdominal aortic aneurysm
wall biology, Eur. J. Vasc. Endovasc. Surg. 39 (2010) 569–576.
[35] J. Li, J.J. Li, J.G. He, J.L. Nan, Y.L. Guo, C.M. Xiong, Atorvastatin decreases C-
reactive protein-induced inflammatory response in pulmonary artery smooth
muscle cells by inhibiting nuclear factor-kappaB pathway, Cardiovasc. Ther. 28
(2010) 8–14.
[36] W. Dichtl, J. Dulak, M. Frick, H.F. Alber, S.P. Schwarzacher, M.P. Ares, et al.,
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in
human endothelial and vascular smooth muscle cells, Arterioscler. Thromb. Vasc.
Biol. 23 (2003) 58–63.
[37] W. Ni, K. Egashira, C. Kataoka, S. Kitamoto, M. Koyanagi, S. Inoue, et al.,
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase in-
hibitors in a rat model of chronic inhibition of nitric oxide synthesis, Circ. Res. 89
(2001) 415–421.
[38] R.M. Bell, D.M. Yellon, Atorvastatin, administered at the onset of reperfusion, and
independent of lipid lowering, protects the myocardium by up-regulating a pro-
survival pathway, J. Am. Coll. Cardiol. 41 (2003) 508–515.
[39] Y. Jiao, F. Hu, Z. Zhang, K. Gong, X. Sun, A. Li, et al., Efficacy and safety of
Loading-Dose rosuvastatin therapy in elderly patients with acute coronary syn-
dromes undergoing elective percutaneous coronary intervention, Clin. Drug
Investig. 35 (2015) 777–784.
[40] Z. Wang, H. Dai, M. Xing, Z. Yu, X. Lin, S. Wang, et al., Effect of a single high
loading dose of rosuvastatin on percutaneous coronary intervention for acute
coronary syndromes, J. Cardiovasc. Pharmacol. Ther. 18 (2013) 327–333.
[41] G. Patti, V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, et al.,
Atorvastatin pretreatment improves outcomes in patients with acute coronary
syndromes undergoing early percutaneous coronary intervention: results of the
ARMYDA-ACS randomized trial, J. Am. Coll. Cardiol. 49 (2007) 1272–1278.
[42] M. Lewandowski, Z. Kornacewicz-Jach, B. Millo, J. Zielonka, M. Czechowska,
R. Kaliszczak, et al., The influence of low dose atorvastatin on inflammatory
marker levels in patients with acute coronary syndrome and its potential clinical
value, Cardiol. J. 15 (2008) 357–364.
[43] L.C. Correia, A.C. Spósito, J.C. Lima, L.P. Magalhães, L.C. Passos, M.S. Rocha,
et al., Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris
and non–Q-wave acute myocardial infarction, Am. J. Cardiol. 92 (2003) 298–301.
[44] T. Dohi, K. Miyauchi, S. Okazaki, T. Yokoyama, N. Yanagisawa, H. Tamura, et al.,
Early intensive statin treatment for six months improves long-term clinical out-
comes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a
follow-up study, Atherosclerosis 210 (2010) 497–502.
[45] K.H. Yun, M.H. Jeong, S.K. Oh, S.J. Rhee, E.M. Park, E.M. Lee, et al., The beneficial
effect of high loading dose of rosuvastatin before percutaneous coronary inter-
vention in patients with acute coronary syndrome, Int. J. Cardiol. 137 (2009)
246–251.
[46] K.H. Yun, I.-S. Shin, S.-N. Shin, J.-H. Choi, S.H. Kim, S.J. Rhee, et al., Effect of
previous statin therapy in patients with acute coronary syndrome and percuta-
neous coronary intervention, Korean Circ. J. 41 (2011) 458–463.
[47] S.M. Macin, E.R. Perna, E.F. Farías, V. Franciosi, J.R. Cialzeta, M. Brizuela, et al.,
Atorvastatin has an important acute anti-inflammatory effect in patients with
acute coronary syndrome: results of a randomized, double-blind, placebo-con-
trolled study, Am. Heart J. 149 (2005) 451–457.
[48] E. Vasilieva, O. Kasyanova, A. Shpektor, The antiplatelet effect of atorvastatin in
patients with acute coronary syndrome depends on the hs-CRP level, Acute Card.
Care 10 (2008) 181–184.
[49] S. Wassmann, A. Faul, B. Hennen, B. Scheller, M. Böhm, G. Nickenig, Rapid effect
of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary en-
dothelial function, Circ. Res. 93 (2003) e98–e103.
[50] J.-J. Li, Y. Wang, S.-P. Nie, C.-Y. Zhang, Y.-S. Li, R.-T. Hui, et al., Reduction of C-
R. Tabrizi et al. Pharmacological Research 141 (2019) 85–103
101
reactive protein by a single 80 mg of simvastatin in patients with unstable angina,
Clin. Chim. Acta 376 (2007) 163–167.
[51] J.-J. Li, C.-H. Fang, Effects of 4 weeks of atorvastatin administration on the anti-
inflammatory cytokine interleukin-10 in patients with unstable angina, Clin.
Chem. 51 (2005) 1735–1738.
[52] Y. Sawara, T. Takei, K. Uchida, T. Ogawa, T. Yoshida, K. Tsuchiya, et al., Effects of
lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients
with chronic kidney disease, Intern. Med. 47 (2008) 1505–1510.
[53] R.G. Fassett, I.K. Robertson, M.J. Ball, D.P. Geraghty, J.S. Coombes, Effects of
atorvastatin on biomarkers of inflammation in chronic kidney disease, Clin.
Nephrol. 81 (2014) 75–85.
[54] A. Verma, K.M. Ranganna, R.S. Reddy, M. Verma, N.F. Gordon, Effect of rosu-
vastatin on C-reactive protein and renal function in patients with chronic kidney
disease, Am. J. Cardiol. 96 (2005) 1290–1292.
[55] S.-H. Jo, B.-K. Koo, J.-S. Park, H.-J. Kang, Y.-S. Cho, Y.-J. Kim, et al., Prevention of
radiocontrast medium–induced nephropathy using short-term high-dose simvas-
tatin in patients with renal insufficiency undergoing coronary angiography
(PROMISS) trial—a randomized controlled study, Am. Heart J. 155 (499) (2008)
e1–e8.
[56] P. Marschang, G.J. Friedrich, H. Ditlbacher, A. Stoeger, D. zur Nedden,
R. Kirchmair, et al., Reduction of soluble P-selectin by statins is inversely corre-
lated with the progression of coronary artery disease, Int. J. Cardiol. 106 (2006)
183–190.
[57] K.C. Chan, H.H. Chou, C.N. Huang, M.C. Chou, Atorvastatin administration after
percutaneous coronary intervention in patients with coronary artery disease and
normal lipid profiles: impact on plasma adiponectin level, Clin. Cardiol. 31 (2008)
253–258.
[58] T. Suzuki, T. Nozawa, M. Sobajima, N. Igarashi, A. Matsuki, N. Fujii, et al.,
Atorvastatin-induced changes in plasma coenzyme Q10 and brain natriuretic
peptide in patients with coronary artery disease, Int. Heart J. 49 (2008) 423–433.
[59] R.R. Azar, G. Badaoui, A. Sarkis, R. Kassab, E. Salamé, S. Klaymé, et al., Effects of
tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and so-
luble CD40 ligand following percutaneous coronary interventions in patients with
stable coronary artery disease, Am. J. Cardiol. 95 (2005) 236–240.
[60] I. Karaca, E. Ilkay, M. Akbulut, M. Yavuzkır, M. Pekdemir, H. Akbulut, et al.,
Atorvastatin affects C-reactive protein levels in patients with coronary artery
disease, Curr. Med. Res. Opin. 19 (2003) 187–191.
[61] M. Abe, N. Maruyama, K. Okada, S. Matsumoto, K. Matsumoto, M. Soma, Effects of
lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in
patients with diabetic nephropathy, J. Atheroscler. Thromb. 18 (2011)
1018–1028.
[62] K.A. Dornbrook‐Lavender, M.S. Joy, C.J. Denu‐Ciocca, H. Chin, S.L. Hogan,
J.A. Pieper, Effects of atorvastatin on low‐density lipoprotein cholesterol pheno-
type and C‐Reactive protein levels in patients undergoing long‐term Dialysis,
Pharmacotherapy 25 (2005) 335–344.
[63] M. Tugrul Sezer, S. Katirci, M. Demir, J. Erturk, S. Adana, S. Kaya, Short-term
effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis
patients, Scand. J. Urol. Nephrol. 41 (2007) 436–441.
[64] M. Arabul, M. Gullulu, Y. Yilmaz, I. Akdag, S. Kahvecioglu, M.A. Eren, et al., Effect
of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease,
Clin. Biochem. 41 (2008) 1055–1058.
[65] E. Abulhul, K. McDonald, R. Martos, D. Phelan, J.P. Spiers, M. Hennessy, et al.,
Long-term statin therapy in patients with systolic heart failure and normal cho-
lesterol: effects on elevated serum markers of collagen turnover, inflammation,
and B-type natriuretic peptide, Clin. Ther. 34 (2012) 91–100.
[66] D. Kirmizis, A. Papagianni, F. Dogrammatzi, L. Skoura, A.-M. Belechri,
E. Alexopoulos, et al., Effects of simvastatin on markers of inflammation, oxidative
stress and endothelial cell apoptosis in patients on chronic hemodialysis, J.
Atheroscler. Thromb. 17 (2010) 1256–1265.
[67] J.W. Chang, W.S. Yang, W.K. Min, S.K. Lee, J.S. Park, S.B. Kim, Effects of sim-
vastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis
patients, Am. J. Kidney Dis. 39 (2002) 1213–1217.
[68] J.E. Burmeister, D.R. Miltersteiner, B.M. Campos, Rosuvastatin in hemodialysis:
short-term effects on lipids and C-reactive protein, J. Nephrol. 22 (2009) 83.
[69] A. Ichihara, M. Hayashi, M. Ryuzaki, M. Handa, T. Furukawa, T. Saruta,
Fluvastatin prevents development of arterial stiffness in haemodialysis patients
with type 2 diabetes mellitus, Nephrol. Dial. Transplant. 17 (2002) 1513–1517.
[70] C.-J. Ge, S.-Z. Lu, Y.-D. Chen, X.-F. Wu, S.-J. Hu, Y. Ji, Synergistic effect of am-
lodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-
reactive protein in hypertensive patients with primary hypercholesterolemia,
Heart Vessels 23 (2008) 91–95.
[71] H. Yamagami, M. Sakaguchi, S. Furukado, T. Hoshi, Y. Abe, H. Hougaku, et al.,
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic pa-
tients, Ultrasound Med. Biol. 34 (2008) 1353–1359.
[72] K.K. Koh, J.W. Son, J.Y. Ahn, D.K. Jin, H.S. Kim, Y.M. Choi, et al., Vascular effects
of diet and statin in hypercholesterolemic patients, Int. J. Cardiol. 95 (2004)
185–191.
[73] K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, J.Y. Ahn, S.J. Kim, et al., Simvastatin
improves flow-mediated dilation but reduces adiponectin levels and insulin sen-
sitivity in hypercholesterolemic patients, Diabetes Care 31 (2008) 776–782.
[74] K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, E.K. Shin, Atorvastatin causes
insulin resistance and increases ambient glycemia in hypercholesterolemic pa-
tients, J. Am. Coll. Cardiol. 55 (2010) 1209–1216.
[75] K.K. Koh, M.J. Quon, S.H. Han, Y. Lee, S.J. Kim, J.B. Park, et al., Differential
metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients,
Atherosclerosis 204 (2009) 483–490.
[76] K.K. Koh, M.J. Quon, I. Sakuma, Y. Lee, S. Lim, S.H. Han, et al., Effects of sim-
vastatin therapy on circulating adipocytokines in patients with hypercholester-
olemia, Int. J. Cardiol. 146 (2011) 434–437.
[77] K.K. Koh, P.C. Oh, I. Sakuma, E.Y. Kim, Y. Lee, T. Hayashi, et al., Vascular and
metabolic effects of ezetimibe combined with simvastatin in patients with hy-
percholesterolemia, Int. J. Cardiol. 199 (2015) 126–131.
[78] L. Nilsson, P. Eriksson, P. Cherfan, L. Jonasson, Effects of simvastatin on proin-
flammatory cytokines and matrix metalloproteinases in hypercholesterolemic in-
dividuals, Inflammation 34 (2011) 225–230.
[79] E. Ascer, M.C. Bertolami, M.L. Venturinelli, V. Buccheri, J. Souza, J.C. Nicolau,
et al., Atorvastatin reduces proinflammatory markers in hypercholesterolemic
patients, Atherosclerosis 177 (2004) 161–166.
[80] A.M. Kuklińska, B. Mroczko, W.J. Musiał, R. Sawicki, A. Kozieradzka, M. Usowicz-
Szaryńska, et al., Hypotensive effect of atorvastatin is not related to changes in
inflammation and oxidative stress, Pharmacol. Rep. 62 (2010) 883–890.
[81] J.J. McMurray, J. Kjekshus, L. Gullestad, P. Dunselman, Å Hjalmarson, H. Wedel,
et al., Effects of statin therapy according to plasma high-sensitivity C-reactive
protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart
Failure (CORONA): a retrospective analysis, Circulation 120 (2009) 2188–2196.
[82] X. Zhang, X. Zeng, L. Dong, X. Zhao, X. Qu, The effects of statins on benign pro-
static hyperplasia in elderly patients with metabolic syndrome, World J. Urol. 33
(2015) 2071–2077.
[83] U. Singh, S. Devaraj, I. Jialal, D. Siegel, Comparison effect of atorvastatin (10
versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with
metabolic syndrome, Am. J. Cardiol. 102 (2008) 321–325.
[84] A. Oguz, M. Uzunlulu, Short term fluvastatin treatment lowers serum asymmetric
dimethylarginine levels in patients with metabolic syndrome, Int. Heart J. 49
(2008) 303–311.
[85] S. Devaraj, D. Siegel, I. Jialal, Simvastatin (40 mg/day), adiponectin levels, and
insulin sensitivity in subjects with the metabolic syndrome, Am. J. Cardiol. 100
(2007) 1397–1399.
[86] L. Nafasi, R. Rahmani, A. Shafiee, A. Salari, A. Abdollahi, A. Meysamie, Can a high
reloading dose of atorvastatin prior to percutaneous coronary intervention reduce
periprocedural myocardial infarction? Curr. Med. Res. Opin. 30 (2014) 381–386.
[87] D.C. Chan, G.F. Watts, P.H.R. Barrett, L.J. Beilin, T.A. Mori, Effect of atorvastatin
and fish oil on plasma high-sensitivity C-reactive protein concentrations in in-
dividuals with visceral obesity, Clin. Chem. 48 (2002) 877–883.
[88] J. Puurunen, T. Piltonen, K. Puukka, A. Ruokonen, M.J. Savolainen, R. Bloigu,
et al., Statin therapy worsens insulin sensitivity in women with polycystic ovary
syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled
study, J. Clin. Endocrinol. Metab. 98 (2013) 4798–4807.
[89] T. Sathyapalan, J. Shepherd, C. Arnett, A.M. Coady, E.S. Kilpatrick, S.L. Atkin,
Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with
polycystic ovary syndrome, Clin. Chem. 56 (2010 Nov) 1696–1700.
[90] N. Raja-Khan, A.R. Kunselman, C.S. Hogeman, C.M. Stetter, L.M. Demers,
R.S. Legro, Effects of atorvastatin on vascular function, inflammation, and an-
drogens in women with polycystic ovary syndrome: a double-blind, randomized,
placebo-controlled trial, Fertil. Steril. 95 (April) (2011) 1849–1852.
[91] S. Guo, R. Wang, Z. Yang, K. Li, Q. Wang, Effects of atorvastatin on serum lipids,
serum inflammation and plaque morphology in patients with stable athero-
sclerotic plaques, Exp. Ther. Med. 1 (December(4)) (2012) 1069–1074.
[92] M. Lunder, M. Janić, V. Savić, A. Janež, K. Kanc, M. Šabovič, Very low-dose flu-
vastatin-valsartan combination decreases parameters of inflammation and oxida-
tive stress in patients with type 1 diabetes mellitus, Diabetes Res. Clin. Pract. 1
(May (127)) (2017) 181–186.
[93] P.G. Fegan, A.C. Shore, D. Mawson, J.E. Tooke, K.M. MacLeod, Microvascular
endothelial function in subjects with Type 2 diabetes and the effect of lipid‐low-
ering therapy, Diabet. Med. 1 (December (22)) (2005) 1670–1676.
[94] E. Konduracka, D. Galicka‐Latala, G. Cieslik, P. Rostoff, D. Fedak, J. Sieradzki,
et al., Effect of atorvastatin on endothelial function and inflammation in long‐-
duration type 1 diabetic patients without coronary heart disease and arterial hy-
pertension, Diabetes Obes. Metab. 1 (September (10)) (2008) 719–725.
[95] M.A. Van de Ree, M.V. Huisman, H.M. Princen, A.E. Meinders, C. Kluft, Strong
decrease of high sensitivity C-reactive protein with high-dose atorvastatin in pa-
tients with type 2 diabetes mellitus, Atherosclerosis. 1 (January (166)) (2003)
129–135.
[96] P.A. Economides, A. Caselli, E. Tiani, L. Khaodhiar, E.S. Horton, A. Veves, The
effects of atorvastatin on endothelial function in diabetic patients and subjects at
risk for type 2 diabetes, J. Clin. Endocrinol. Metab. 1 (February (89)) (2004)
740–747.
[97] H. Ghanim, K. Green, S. Abuaysheh, R. Patel, M. Batra, A. Chaudhuri, et al.,
Ezetimibe and simvastatin combination inhibits and reverses the pro-in-
flammatory and pro-atherogenic effects of cream in obese patients,
Atherosclerosis. 1 (August (263)) (2017) 278–286.
[98] M.S. Joy, K.A. Dornbrook-Lavender, H. Chin, S.L. Hogan, C. Denu-Ciocca, Effects
of atorvastatin on Lp (a) and lipoprotein profiles in hemodialysis patients, Ann.
Pharmacother. 42 (January) (2008) 9–15.
[99] Y. Luo, D. Jiang, D. Wen, J. Yang, L. Li, Changes in serum interleukin-6 and high-
sensitivity C-reactive protein levels in patients with acute coronary syndrome and
their responses to simvastatin, Heart Vessels 1 (November (19)) (2004) 257–262.
[100] M. Goicoechea, S.G. de Vinuesa, V. Lahera, V. Cachofeiro, F. Gómez-Campderá,
A. Vega, et al., Effects of atorvastatin on inflammatory and fibrinolytic parameters
in patients with chronic kidney disease, J. Am. Soc. Nephrol. 1 (December) (2006)
S231–S235.
[101] I.D. Strazhesko, O.N. Tkacheva, D.U. Akasheva, E.N. Dudinskaya, E.V. Plokhova,
V.S. Pykhtina, et al., Atorvastatin therapy modulates telomerase activity in
R. Tabrizi et al. Pharmacological Research 141 (2019) 85–103
102
patients free of atherosclerotic cardiovascular diseases, Front. Pharmacol. 30
(September) (2016) 347.
[102] X.Y. Li, J.P. Chang, Z.W. Su, J.H. Li, B.S. Peng, S.L. Zhu, et al., How does short‐-
term low‐dose simvastatin influence serum prohepcidin levels in patients with
end‐stage renal disease? A pilot study, Ther. Apher. Dial. 1 (June (14)) (2010)
308–314.
[103] Y.C. Doo, S.J. Han, S.W. Han, W.J. Park, S.H. Choi, G.Y. Cho, et al., Effect of
preexisting statin use on expression of C‐reactive protein, adhesion molecules,
interleukin‐6, and antioxidized low‐density lipoprotein antibody in patients with
unstable angina undergoing coronary stenting, Clin. Cardiol. 1 (February (28))
(2005) 72–76.
[104] O. Gruzdeva, E. Uchasova, Y. Dyleva, O. Akbasheva, V. Karetnikova, O. Barbarash,
Early effects of treatment low-dose atorvastatin on markers of insulin resistance
and inflammation in patients with myocardial infarction, Front. Pharmacol. 7
(2016) 324.
[105] I. Andreou, D. Tousoulis, A. Miliou, C. Tentolouris, K. Zisimos, P. Gounari, et al.,
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart
failure: a randomized placebo-controlled study, Atherosclerosis 210 (2010)
194–198.
[106] A. Nakagomi, Y. Seino, K. Kohashi, M. Kosugi, Y. Endoh, Y. Kusama, et al., Effects
of statin therapy on the production of monocyte pro-inflammatory cytokines,
cardiac function, and long-term prognosis in chronic heart failure patients with
dyslipidemia, Circ. J. 76 (2012) 2130–2138.
[107] F.M. Doh, T.-I. Chang, H.M. Koo, M.J. Lee, D.H. Shin, C.H. Kim, et al., The effect of
HMG-CoA reductase inhibitor on insulin resistance in patients undergoing peri-
toneal dialysis, Cardiovasc. Drugs Ther. 26 (2012) 501–509.
[108] I. Goncalves, P. Cherfan, I. Söderberg, G. Nordin Fredrikson, L. Jonasson, Effects of
simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with
immune stimulation markers, Autoimmunity. 42 (2009) 203–208.
[109] P. Ostadal, D. Alan, P. Hajek, D. Horak, J. Vejvoda, J. Trefanec, et al., The effect of
early treatment by cerivastatin on the serum level of C-reactive protein, inter-
leukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave
myocardial infarction, Vascular Biochemistry, Springer, 2003, pp. 45–50.
[110] A. Link, T. Ayadhi, M. Böhm, G. Nickenig, Rapid immunomodulation by rosu-
vastatin in patients with acute coronary syndrome, Eur. Heart J. 27 (2006)
2945–2955.
[111] J. Yang, X.-P. Li, S.-P. Zhao, J. Li, J.-D. Li, X.-M. Xie, The effect of different doses of
fluvastatin on inflammatory markers in the early phase of acute coronary syn-
drome, Clin. Chim. Acta 368 (2006) 183–187.
[112] N. Kishimoto, T. Hayashi, I. Sakuma, H. Kano-Hayashi, T. Tsunekawa, M. Osawa,
et al., A hydroxymethylglutaryl coenzyme a reductase inhibitor improves en-
dothelial function within 7 days in patients with chronic hemodialysis, Int. J.
Cardiol. 145 (2010) 21–26.
[113] E. Stefanadi, D. Tousoulis, C. Antoniades, V. Katsi, E. Bosinakou, E. Vavuranakis,
et al., Early initiation of low-dose atorvastatin treatment after an acute ST-elevated
myocardial infarction, decreases inflammatory process and prevents endothelial
injury and activation, Int. J. Cardiol. 133 (2009) 266–268.
[114] M.M. Pereira, T.P.S.A. Santos, R. Aras, R.D. Couto, M.L.B.S. Atta, A.M. Atta, Serum
levels of cytokines and chemokines associated with cardiovascular disease in
Brazilian patients treated with statins for dyslipidemia, Int. Immunopharmacol. 18
(2014) 66–70.
[115] D. Tousoulis, C. Antoniades, V. Katsi, E. Bosinakou, M. Kotsopoulou, C. Tsioufis,
et al., The impact of early administration of low-dose atorvastatin treatment on
inflammatory process, in patients with unstable angina and low cholesterol level,
Int. J. Cardiol. 109 (2006) 48–52.
[116] H. Nawawi, N. Osman, K. Yusoff, B. Khalid, Reduction in serum levels of adhesion
molecules, interleukin-6 and C-reactive protein following short-term low-dose
atorvastatin treatment in patients with non-familial hypercholesterolemia, Horm.
Metab. Res. 35 (2003) 479–485.
[117] A. Gómez-García, G.M. Torres, L.E. Ortega-Pierres, E. Rodríguez-Ayala, C. Álvarez-
Aguilar, Rosuvastatin and metformin decrease inflammation and oxidative stress
in patients with hypertension and dyslipidemia, Rev. Esp. Cardiol. 60 (2007)
1242–1249.
[118] D. Tousoulis, C. Antoniades, E. Bosinakou, M. Kotsopoulou, C. Pitsavos,
C. Vlachopoulos, et al., Effects of atorvastatin on reactive hyperemia and in-
flammatory process in patients with congestive heart failure, Atherosclerosis 178
(2005) 359–363.
[119] D. Tousoulis, C. Antoniades, C. Vassiliadou, M. Toutouza, C. Pitsavos,
C. Tentolouris, et al., Effects of combined administration of low dose atorvastatin
and vitamin E on inflammatory markers and endothelial function in patients with
heart failure, Eur. J. Heart Fail. 7 (2005) 1126–1132.
[120] D. Tousoulis, C. Antoniades, C. Vasiliadou, P. Kourtellaris, K. Koniari, K. Marinou,
et al., Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow,
asymmentrical dimethylarginine levels and the inflammatory process in patients
with type 2 diabetes mellitus, Heart 93 (2007) 244–246.
[121] P. Usharani, A. Mateen, M. Naidu, Y. Raju, N. Chandra, Effect of NCB-02, ator-
vastatin and placebo on endothelial function, oxidative stress and inflammatory
markers in patients with type 2 diabetes mellitus, Drugs in R & D 9 (2008)
243–250.
[122] R. Krysiak, W. Żmuda, B. Okopień, The effect of short-term simvastatin treatment
on plasma adipokine levels in patients with isolated hypercholesterolemia: a
preliminary report, Pharmacol. Rep. 66 (2014) 880–884.
[123] W. Xie, P. Li, Z. Wang, J. Chen, Z. Lin, X. Liang, et al., Rosuvastatin may reduce the
incidence of cardiovascular events in patients with acute coronary syndromes
receiving percutaneous coronary intervention by suppressing miR‐155/SHIP‐1
signaling pathway, Cardiovasc. Ther. 32 (2014) 276–282.
[124] K.K. Koh, J.W. Son, J.Y. Ahn, D.K. Jin, H.S. Kim, Y.M. Choi, et al., Comparative
effects of diet and statin on NO bioactivity and matrix metalloproteinases in hy-
percholesterolemic patients with coronary artery disease, Arterioscler. Thromb.
Vasc. Biol. 22 (2002) e19–e23.
[125] S. Zhao, Q. Li, L. Liu, Z. Xu, J. Xiao, Simvastatin reduces interleukin-1β secretion
by peripheral blood mononuclear cells in patients with essential hypertension,
Clin. Chim. Acta 344 (2004) 195–200.
[126] S. Huptas, H.C. Geiss, C. Otto, K.G. Parhofer, Effect of atorvastatin (10 mg/day) on
glucose metabolism in patients with the metabolic syndrome, Am. J. Cardiol. 1
(July (98)) (2006) 66–69.
[127] B. Banaszewska, L. Pawelczyk, R.Z. Spaczynski, J. Dziura, A.J. Duleba, Effects of
simvastatin and oral contraceptive agent on polycystic ovary syndrome: pro-
spective, randomized, crossover tria, J. Clin. Endocrinol. Metab. 14 (November
(92)) (2006) 456–461.
[128] A.M. Cueto-Manzano, J.R. Ángel-Zúñiga, G. Ornelas-Carrillo, E. Rojas-Campos,
H.R. Martínez-Ramírez, Cortés-Sanabria, Anti-inflammatory interventions in end-
stage kidney disease: a randomized, double-blinded, controlled and crossover
clinical trial on the use of pravastatin in continuous ambulatory peritoneal dia-
lysis, Arch. Med. Res. 44 (2013) 633–637.
[129] A.M. Wägner, J.L. Sánchez-Quesada, S. Benítez, C. Bancells, J. Ordóñez-Llanos,
A. Pérez, Effect of statin and fibrate treatment on inflammation in type 2 diabetes.
A randomized, cross-over study, Diabetes Res. Clin. Pract. 1 (July (93)) (2011)
25–28.
[130] G.K. Dogra, G.F. Watts, D.C. Chan, K. Stanton, Statin therapy improves brachial
artery vasodilator function in patients with Type 1 diabetes and micro-
albuminuria, Diabet. Med. 1 (March (22)) (2005) 239–242.
[131] M.B.S. Moohebati, M.R. Azarpazhooh, M.H. Daloee, M. Ghayour-Mobarhan,
S. Tavallaie, M. Amini, A. Momenzadeh, A. Sahebkar, R. Paydar, A.A. Rahsepar,
Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in
dyslipidemic patients: a randomized, double-blind, placebo-controlled, cross-over
trial, Clin. Biochem. 1 (February (44)) (2011) 192–197.
[132] H.E.S.E. Bays, A.K. Shah, D.L. Maccubbin, Y.B. Mitchel, M. Mercuri, Effects of
simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceri-
demic patients, Am. J. Cardiol. 1 (November (90)) (2002) 942–946.
[133] H.E.O.L. Bays, N. Fraser, D.L. Tribble, K. Quinto, R. Reyes, A.O. Johnson-Levonas,
A. Sapre, S.R. Donahue, A multicenter, randomized, double-blind, placebo-con-
trolled, factorial design study to evaluate the lipid-altering efficacy and safety
profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvas-
tatin monotherapy in patients with primary hypercholesterolemia, Clin. Ther. 1
(November (26)) (2004) 1758–1773.
[134] M.R.E. Farnier, B. Gil-Extremera, G.F. Mendez, G. Macdonell, C. Hamlin,
I. Perevozskaya, M.J. Davies, D. Kush, Y.B. Mitchel, Efficacy and safety of the
coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed
hyperlipidemia, Am. Heart J. 1 (February (153)) (2007) 335-e1.
[135] A.C.S.A. Goldberg, J. Liu, R. Capece, Y.B. Mitchel, Efficacy and safety of ezetimibe
coadministered with simvastatin in patients with primary hypercholesterolemia: a
randomized, double-blind, placebo-controlled trial, In Mayo Clin. Proc. 1 (May
(79)) (2004) 620–629.
[136] T.M.D.Y. Lu, H.B. Leu, W.H. Yin, W.H. Sheu, K.M. Chu, Effect of rosuvastatin on
plasma levels of asymmetric dimethylarginine in patients with hypercholester-
olemia, Am. J. Cardiol. 15 (July (94)) (2004) 157–161.
[137] K.C.C.W. Tan, S.C. Tam, V.H. Ai, C.H. Lam, K.S. Lam, Atorvastatin lowers C-re-
active protein and improves endothelium-dependent vasodilation in type 2 dia-
betes mellitus, J. Clin. Endocrinol. Metab. 1 (February (87)) (2002) 563–568.
[138] A.K.H. Strom, S. Martin, C. Herder, M.C. Simon, W. Koenig, T. Heise,
L. Heinemann, M. Roden, N.C. Schloot, DIATOR Study Group.IMproved pre-
servation of residual beta cell function by atorvastatin in patients with recent onset
type 1 diabetes and high CRP levels (DIATOR trial), PLoS One 20 (March (7))
(2012) e33108.
[139] G.R.P. Rudofsky, J.B. Groener, Z. Djuric, T. Fleming, C. Metzner, I.A. Grafe,
A. Bierhaus, P.P. Nawroth, Identical LDL-cholesterol lowering but non-identical
effects on NF-κB activity: high dose simvastatin vs combination therapy with
ezetimibe, Atherosclerosis 1 (July (223)) (2012) 190–196.
[140] L.C.C. Vernaglione, P. Muscogiuri, S. Chimienti, Does atorvastatin influence serum
C-reactive protein levels in patients on long-term hemodialysis? Am. J. Kidney Dis.
1 (March (43)) (2004) 471–478.
[141] T.J.S. Almquist, F. Mobarrez, P. Näsman, P. Hjemdahl, Lipid‐lowering treatment
and inflammatory mediators in diabetes and chronic kidney disease, Eur. J. Clin.
Invest. 1 (March(44)) (2014) 276–284.
[142] Folkeringa R.J. dVC, Y.M. Pinto, J. Habets, P.W. De Leeuw, R.G. Tieleman,
M.H. Prins, M. Van Dieijen-Visser, H.J. Crijns, No effect of rosuvastatin on left
ventricular hypertrophy in patients with hypertension: a prospective randomised
open-label study with blinded endpoint assessment, Int. J. Cardiol. 5
(November145) (2010) 156–158.
R. Tabrizi et al. Pharmacological Research 141 (2019) 85–103
103
